ClinicalTrials.gg
CompletedNCT00281658Updated Feb 10, 2023Results posted

Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2

A Phase 3 interventional study of Lapatinib (GW572016) oral tablets and Paclitaxel infusion in Neoplasms, Breast, sponsored by Novartis Pharmaceuticals. Completed at 54 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
444
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies testing lapatinib in Breast Neoplasms — none open to participants now, 3 under way, 1 of them phase 3. Lapatinib · Breast Neoplasms.

Enrollment
9th of 114
444 · median 35
Started
2006
with 12 others
Phase 3
18 of 114
none open now
Registered
17th of 114
by date
Lead sponsor
15 of 114
Novartis Pharmaceuticals

Among the 114 studies testing lapatinib in Breast Neoplasms, this one is the 9th largest by enrollment, is one of 13 that started in 2006, is one of 18 in phase 3, and was the 17th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 114 studies testing lapatinib in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About lapatinib

Lapatinib: first FDA approval 2007 (TYKERB), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 114 studies testing lapatinib in Breast Neoplasms as a file.
02

Study summary

This was a randomized, double-blind, placebo-controlled, multicenter, Phase III study to evaluate and compare the efficacy and safety of Lapatinib + Paclitaxel versus Placebo + Paclitaxel in men and women with ErbB2 amplified metastatic (Stage IV) breast cancer who had not received prior therapy for metastatic disease.

Read the detailed description

Subjects were randomized to receive either Lapatinib (1500 mg once daily) + Paclitaxel (80 mg/m2 IV weekly for 3 weeks every 4 weeks) or Placebo (once daily) + Paclitaxel (80 mg/m2 IV weekly for 3 weeks every 4 weeks).

Subjects who progressed while on study and were on the placebo+paclitaxel arm were permitted to enter an extension phase of open label monotherapy therapy with lapatinib or open label combination therapy with lapatinib+paclitaxel and followed for response, progression and survival.

Based on the positive results in the primary analysis, Protocol Amendment 02 (dated 09 May 2011) discontinued further entry into the lapatinib monotherapy extension phase, and ongoing subjects taking placebo were permitted to replace it with open label lapatinib therapy (with or without continued paclitaxel therapy).

Following the primary Overall Survival (OS) analysis and subsequent implementation of Protocol Amendment 03, subjects who were still receiving active treatment entered the Long-term follow-up (LTFU) phase of the study. Reporting requirements in the LTFU phase were limited to Adverse events of special interest (AESI), Serious adverse events (SAEs) and pregnancy, and the subjects continued to receive treatment until the occurrence of unacceptable toxicity or disease progression (as determined by the investigator) or permanent withdrawal from treatment for any reason. Subjects who were no longer receiving active treatment were withdrawn from the study.

03

Conditions studied

  • Neoplasms, Breast

Browse trials for

Keywords

  • ErbB2 positive
  • human epidermal growth factor receptor 2 positive (Her2+)
  • metastatic breast cancer
  • Fluorescence in situ hybridization (FISH) positive
  • Stage IV
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed ;
  • Male or female ≥18 years;
  • confirmed invasive breast cancer with stage IV disease; If the disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by cytology or histology.
  • Documented amplification of ErbB2 by fluorescence in situ hybridization (FISH) in primary or tumor tissue by the central laboratory for randomization into the study;
  • If a taxane was administered in the or adjuvant setting, progression must have occurred >12 months after completion of this treatment and the patient recovered from all associated toxicities;
  • (s) according to (Response Evaluation Criteria in Solid Tumors);
  • Radiotherapy as palliative treatment for painful metastatic disease is permitted but must have been stopped within 2 weeks prior to initiation of any treatment. All subjects must have recovered from all radiotherapy related toxicities prior to initiation of any investigational treatment. The site of radiotherapy must not be used as a site of measurable disease;
  • Bisphosphonate therapy for bone metastases and is allowed; however, treatment must be initiated prior to the first dose of investigational treatment. Prophylactic use of bisphosphonates in subjects without bone disease is not permitted, except for the treatment of osteoporosis;
  • For those patients whose disease is ER+ and/or PR+ the following criteria should be met:

Patients with visceral disease that requires chemotherapy (eg., patients with liver or lung metastases) Rapidly progressing or life threatening disease, as determined by the investigator Patients who received hormonal therapy and are no longer benefiting from this therapy and the hormonal treatment must have been stopped before the first dose of investigational treatment;

  • Cardiac within institutional range of normal as measured by echocardiogram. MUGA scans will be accepted in cases where an echocardiogram cannot be performed or is inconclusive;
  • Performance Status of 0 to 1;
  • of ≥ 12 weeks;
  • Able to swallow and retain oral medication;
  • Archived tumor tissue available for testing;
  • Women and men with potential to have children must be willing to practice acceptable methods of during the study;
  • Willing to complete all screening assessments as outlined in the protocol;
  • Adequate organ function as defined in Table 1 Baseline Laboratory Values;

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating females at anytime during the study
  • Subjects with only non-measurable sites of disease per , (e.g. bone metastases, pleural effusion, or ascites, etc. (Refer to Section 5.3 Efficacy for list sites considered to be non-.);
  • Received prior chemotherapy, immunotherapy, biologic therapy, or anti-ErbB1/ErbB2 therapy for metastatic disease.
  • Prior therapy with an ErbB1 and/or ErbB2 inhibitor, other than trastuzumab in the setting. If trastuzumab was administered in the adjuvant setting, then > 12 months must have elapsed since completion of trastuzumab therapy;
  • Planned concurrent anti-cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy) while taking treatment;
  • Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior cancer treatment;
  • Peripheral neuropathy of Grade 2 or greater;
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis are also excluded;
  • History of other . However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, are eligible;
  • Concurrent disease or condition that would make the subject inappropriate for study participation, or any serious medical disorder that would interfere with the subject's safety;
  • Uncontrolled infection;
  • Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of ;
  • Known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure;
  • Known history or clinical evidence of central nervous system (CNS) metastases or ;
  • Concurrent treatment with prohibited medications, including herbal remedies and Chinese traditional medicines;
  • Concurrent treatment with an investigational agent or participation in another clinical trial involving investigational agents;
  • Used an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of investigational treatment;
  • Known immediate or delayed reaction or idiosyncrasy to drugs chemically related to paclitaxel or lapatinib or their .
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
444 participants (actual)

Study arms

  • Experimental
    Paclitaxel and Lapatinib (Blinded)

    Paclitaxel and Lapatinib (Blinded)

    Drug: Lapatinib (GW572016) oral tablets · Drug: Paclitaxel infusion

  • Active comparator
    Paclitaxel and Placebo (Blinded)

    Paclitaxel and Placebo (Blinded)

    Drug: Paclitaxel infusion · Drug: Placebo

  • Other
    Open Label - Monotherapy (Extension Phase)

    Open Label - Monotherapy (Lapatinib)

    Drug: Lapatinib (GW572016) oral tablets

  • Other
    Open Label - Combination Therapy (Extension Phase)

    Open Label - Combination Therapy (Lapatinib and Paclitaxel)

    Drug: Lapatinib (GW572016) oral tablets · Drug: Paclitaxel infusion

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS) at 53 Months

    Overall Survival (OS) was defined as the interval of time (in months) between the date of randomization and the date of death due to any cause.

    Time frame: From date of randomization until date of death from any cause, assessed up to 53 months (Primary OS analysis cut-off date = 18-Jun-2010)

Secondary outcomes

  1. Overall Survival (OS) at 190 Months

    Overall Survival (OS) was defined as the interval of time (in months) between the date of randomization and the date of death due to any cause.

    Time frame: From date of randomization until date of death from any cause, assessed up to 190 months (Final OS analysis cut-off date = 23-Nov-2021)

  2. Progression-free Survival (PFS) by Investigator Assessment

    Progression-free survival (PFS) during the randomized phase was defined as the interval of time (in months) between the date of randomization and the earlier of date of disease progression (radiological or clinical assessment of symptomatic progression), or date of death due to any cause.

    Time frame: From date of randomization until date of progression or date of death from any cause, whichever comes first, assessed up to 190 months (Final analysis cut-off date = 23-Nov-2021)

  3. Overall Response Rate (ORR) by Investigator Assessment

    Overall response rate (ORR) during the randomized phase was evaluated per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) and defined as the percentage of subjects achieving either a Complete Response (CR) or a Partial Response (PR). Participants with unknown or missing responses were treated as non-responders.

    Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 190 months (Final analysis cut-off date = 23-Nov-2021)

  4. Clinical Benefit Rate (CBR)

    Clinical benefit rate (CBR) was defined as the percentage of subjects with evidence of CR or PR or stable disease (neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of \>=1 new lesions\], taking as reference the smallest sum LD since treatment start) of \>=24 weeks, based on confirmed responses from the investigator assessment of best overall response during the randomized phase.

    Time frame: From date of randomization until date of progression or date of death from any cause, whichever comes first, assessed up to 53 months (Primary analysis cut-off date = 18-Jun-2010)

  5. Duration of Response (DOR)

    For subjects who show CR or PR, duration of response (DOR) was defined to be the time from first documented evidence of PR or CR until the first documented sign of disease progression (radiological or clinical assessment of symptomatic progression) or death due to any cause, if sooner during the randomized phase.

    Time frame: From date of confirmed CR or PR until date of progression or date of death from any cause, whichever comes first, assessed up to 190 months (Final analysis cut-off date = 23-Nov-2021)

  6. Number of Participants With a CR or PR at Weeks 8, 12, 16, 24, 32, 40, 48, 56, 64, and 72

    The original outcome measure to be analyzed was Time to response (TTR) during the randomized phase defined as the time from randomization until first documented evidence of PR or CR (whichever status was recorded first); however, data were presented as the number of participants with a response at each nominal visit. Responses were based on the investigator's assessment, and only participants with a confirmed CR or PR were included in this analysis.

    Time frame: Weeks 8, 12, 16, 24, 32, 40, 48, 56, 64, and 72

  7. Number of Tumors Evaluable for PIK3CA Mutations

    Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. A PIK3CA mutation test kit was used to assess mutation status on genomic deoxyribonucleic acid (DNA) isolated from tumor tissue.

    Time frame: Baseline

  8. Number of Participants With Tumors Evaluable for PTEN

    Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. Immunohistochemistry (IHC) staining in an analytically validated assay was used in the assessment of PTEN protein expression on tumor tissue. Staining intensity was allocated a score of 0, 1+, 2+ or 3+. Tumors scored IHC 0 were considered as exhibiting an absence of PTEN expression whereas those scored ICH 1+, 2+ or 3+ were considered as exhibiting any PTEN expression, being 3+ the highest expression.

    Time frame: Baseline

  9. Predictive Effect of PIK3CA Mutations Status on Overall Response Rate (ORR)

    ORR was evaluated per RECIST v1.1 and defined as the percentage of subjects achieving either CR or PR. Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. A PIK3CA mutation test kit was used to assess mutation status on genomic deoxyribonucleic acid (DNA) isolated from tumor tissue.

    Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 53 months (Primary OS analysis cut-off date = 18-Jun-2010)

  10. Predictive Effect of PTEN Low on Overall Response Rate (ORR)

    ORR was evaluated per RECIST v1.1 and defined as the percentage of subjects achieving either CR or PR. Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. Immunohistochemistry (IHC) staining in an analytically validated assay was used in the assessment of PTEN protein expression on tumor tissue. Staining intensity was allocated a score of 0, 1+, 2+ or 3+. Tumors scored IHC 0 were considered as exhibiting an absence of PTEN expression whereas those scored ICH 1+, 2+ or 3+ were considered as exhibiting any PTEN expression, being 3+ the highest expression. Tumors scored IHC 0/1+ were considered PTEN low.

    Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 53 months (Primary OS analysis cut-off date = 18-Jun-2010)

  11. Predictive Effect of PIK3CA Mutations Status on Clinical Benefit Rate (CBR)

    CBR was evaluated per RECIST v1.1 and defined as the percentage of subjects achieving CR or PR or stable disease. Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. A PIK3CA mutation test kit was used to assess mutation status on genomic deoxyribonucleic acid (DNA) isolated from tumor tissue.

    Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 53 months (Primary OS analysis cut-off date = 18-Jun-2010)

  12. Predictive Effect of PTEN Low on Clinical Benefit Rate (CBR)

    CBR was evaluated per RECIST v1.1 and defined as the percentage of subjects achieving CR or PR or stable disease. Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. Immunohistochemistry (IHC) staining in an analytically validated assay was used in the assessment of PTEN protein expression on tumor tissue. Staining intensity was allocated a score of 0, 1+, 2+ or 3+. Tumors scored IHC 0 were considered as exhibiting an absence of PTEN expression whereas those scored ICH 1+, 2+ or 3+ were considered as exhibiting any PTEN expression, being 3+ the highest expression. Tumors scored IHC 0/1+ were considered PTEN low.

    Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 53 months (Primary OS analysis cut-off date = 18-Jun-2010)

07

Results

Posted Jun 1, 2011
Limitations and caveats
The data collected for China patients after 01JUL2019 were excluded from analysis due to local regulations in China.

Participant flow

This study was conducted in 43 centers in eight participating countries: Brazil (7), China (20), Hong Kong (3), Pakistan (3), Peru (1), Russian Federation (6), Thailand (2) and Ukraine (1).

Randomized Phase
Participant flow — Randomized Phase
MilestoneLapatinib 1500 mg + PaclitaxelPlacebo + PaclitaxelOpen Label - MonotherapyOpen Label - Combination Therapy
Started22222200
Safety population22222100
Completed13314900
Not completed897300
Withdrew: Adverse event0200
Withdrew: Lost to follow-up342700
Withdrew: Withdrawal by subject8700
Withdrew: Study closed/terminated1100
Withdrew: Disease progression362700
Withdrew: Physician decision1100
Withdrew: Other reasons as defined per protocol4300
Withdrew: Reason for withdrawal unspecified4500
Withdrew: Treatment ongoing1000
Open Label Phase
Participant flow — Open Label Phase
MilestoneLapatinib 1500 mg + PaclitaxelPlacebo + PaclitaxelOpen Label - MonotherapyOpen Label - Combination Therapy
Started001494
Completed001040
Not completed00454
Withdrew: Adverse event0010
Withdrew: Lost to follow-up00162
Withdrew: Withdrawal by subject0032
Withdrew: Disease progression00180
Withdrew: Physician decision0010
Withdrew: Relocation of patient0010
Withdrew: Reason for withdrawal unspecified0050

Outcome measures

PrimaryOverall Survival (OS) at 53 Months

Overall Survival (OS) was defined as the interval of time (in months) between the date of randomization and the date of death due to any cause.

Time frame:
From date of randomization until date of death from any cause, assessed up to 53 months (Primary OS analysis cut-off date = 18-Jun-2010)
Reported as:
Median · months
Overall Survival (OS) at 53 Months
monthsLapatinib 1500 mg + PaclitaxelPlacebo + Paclitaxel
Overall Survival (OS) at 53 Months27.8 (23.2 to 32.2)20.5 (17.9 to 24.3)
Statistical analysis
  • Lapatinib 1500 mg + Paclitaxel vs Placebo + Paclitaxel · Log Rank · p = 0.0062 (Stratified Log-Rank (one-sided)) · Hazard ratio (hr): 0.74 · 95% CI 0.58 to 0.94The treatment hazard ratio based on the proportional hazard model stratifying for metastatic disease sites and hormonal status. A hazard ratio \<1 indicates a lower risk with Lapatinib 1500mg + Paclitaxel compared with Placebo + Paclitaxel.
SecondaryOverall Survival (OS) at 190 Months

Overall Survival (OS) was defined as the interval of time (in months) between the date of randomization and the date of death due to any cause.

Time frame:
From date of randomization until date of death from any cause, assessed up to 190 months (Final OS analysis cut-off date = 23-Nov-2021)
Reported as:
Median · months
Overall Survival (OS) at 190 Months
monthsLapatinib 1500 mg + PaclitaxelPlacebo + Paclitaxel
Overall Survival (OS) at 190 Months27.6 (23.7 to 31.5)20.3 (17.9 to 24.3)
Statistical analysis
  • Lapatinib 1500 mg + Paclitaxel vs Placebo + Paclitaxel · Hazard ratio (hr): 0.80 · 95% CI 0.64 to 0.98The treatment hazard ratio based on the proportional hazard model stratifying for metastatic disease sites and hormonal status. A hazard ratio \<1 indicates a lower risk with Lapatinib 1500mg + Paclitaxel compared with Placebo + Paclitaxel.
SecondaryProgression-free Survival (PFS) by Investigator Assessment

Progression-free survival (PFS) during the randomized phase was defined as the interval of time (in months) between the date of randomization and the earlier of date of disease progression (radiological or clinical assessment of symptomatic progression), or date of death due to any cause.

Time frame:
From date of randomization until date of progression or date of death from any cause, whichever comes first, assessed up to 190 months (Final analysis cut-off date = 23-Nov-2021)
Reported as:
Median · months
Progression-free Survival (PFS) by Investigator Assessment
monthsLapatinib 1500 mg + PaclitaxelPlacebo + Paclitaxel
Progression-free Survival (PFS) by Investigator Assessment9.7 (9.2 to 11.1)6.5 (5.5 to 7.3)
Statistical analysis
  • Lapatinib 1500 mg + Paclitaxel vs Placebo + Paclitaxel · Hazard ratio (hr): 0.54 · 95% CI 0.44 to 0.66The Pike estimator of the treatment hazard ratio based on the log rank test stratifying for metastatic disease sites and hormonal status. A hazard ratio \<1 indicates a lower risk with Lapatinib 1500mg + Paclitaxel compared with Placebo + Paclitaxel.
SecondaryOverall Response Rate (ORR) by Investigator Assessment

Overall response rate (ORR) during the randomized phase was evaluated per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) and defined as the percentage of subjects achieving either a Complete Response (CR) or a Partial Response (PR). Participants with unknown or missing responses were treated as non-responders.

Time frame:
From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 190 months (Final analysis cut-off date = 23-Nov-2021)
Reported as:
Number · Percentage of Participants
Overall Response Rate (ORR) by Investigator Assessment
Percentage of ParticipantsLapatinib 1500 mg + PaclitaxelPlacebo + Paclitaxel
Overall Response Rate (ORR) by Investigator Assessment69 (62.9 to 75.4)50 (42.8 to 56.3)
Statistical analysis
  • Lapatinib 1500 mg + Paclitaxel vs Placebo + Paclitaxel · Odds ratio (or): 2.30 · 95% CI 1.54 to 3.47
SecondaryClinical Benefit Rate (CBR)

Clinical benefit rate (CBR) was defined as the percentage of subjects with evidence of CR or PR or stable disease (neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of \>=1 new lesions\], taking as reference the smallest sum LD since treatment start) of \>=24 weeks, based on confirmed responses from the investigator assessment of best overall response during the randomized phase.

Time frame:
From date of randomization until date of progression or date of death from any cause, whichever comes first, assessed up to 53 months (Primary analysis cut-off date = 18-Jun-2010)
Reported as:
Number · Percentage of Participants
Clinical Benefit Rate (CBR)
Percentage of ParticipantsLapatinib 1500 mg + PaclitaxelPlacebo + Paclitaxel
Clinical Benefit Rate (CBR)75 (68.5 to 80.3)56 (49.1 to 62.5)
Statistical analysis
  • Lapatinib 1500 mg + Paclitaxel vs Placebo + Paclitaxel · Odds ratio (or): 2.34 · 95% CI 1.54 to 3.58
SecondaryDuration of Response (DOR)

For subjects who show CR or PR, duration of response (DOR) was defined to be the time from first documented evidence of PR or CR until the first documented sign of disease progression (radiological or clinical assessment of symptomatic progression) or death due to any cause, if sooner during the randomized phase.

Time frame:
From date of confirmed CR or PR until date of progression or date of death from any cause, whichever comes first, assessed up to 190 months (Final analysis cut-off date = 23-Nov-2021)
Reported as:
Median · months
Duration of Response (DOR)
monthsLapatinib 1500 mg + PaclitaxelPlacebo + Paclitaxel
Duration of Response (DOR)9.3 (7.7 to 10.7)5.8 (5.6 to 7.4)
SecondaryNumber of Participants With a CR or PR at Weeks 8, 12, 16, 24, 32, 40, 48, 56, 64, and 72

The original outcome measure to be analyzed was Time to response (TTR) during the randomized phase defined as the time from randomization until first documented evidence of PR or CR (whichever status was recorded first); however, data were presented as the number of participants with a response at each nominal visit. Responses were based on the investigator's assessment, and only participants with a confirmed CR or PR were included in this analysis.

Time frame:
Weeks 8, 12, 16, 24, 32, 40, 48, 56, 64, and 72
Reported as:
Number · Participants
Number of Participants With a CR or PR at Weeks 8, 12, 16, 24, 32, 40, 48, 56, 64, and 72
ParticipantsLapatinib 1500 mg + PaclitaxelPlacebo + Paclitaxel
Week 89461
Week 124028
Week 16611
Week 2478
Week 3232
Week 4000
Week 4810
Week 5610
Week 6410
Week 7210
SecondaryNumber of Tumors Evaluable for PIK3CA Mutations

Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. A PIK3CA mutation test kit was used to assess mutation status on genomic deoxyribonucleic acid (DNA) isolated from tumor tissue.

Time frame:
Baseline
Reported as:
Count of participants · Participants
Number of Tumors Evaluable for PIK3CA Mutations
ParticipantsLapatinib 1500 mg + PaclitaxelPlacebo + Paclitaxel
PIK3CA mutation2936
PIK3CA wild-type5848
PIK3CA indeterminate1722
SecondaryNumber of Participants With Tumors Evaluable for PTEN

Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. Immunohistochemistry (IHC) staining in an analytically validated assay was used in the assessment of PTEN protein expression on tumor tissue. Staining intensity was allocated a score of 0, 1+, 2+ or 3+. Tumors scored IHC 0 were considered as exhibiting an absence of PTEN expression whereas those scored ICH 1+, 2+ or 3+ were considered as exhibiting any PTEN expression, being 3+ the highest expression.

Time frame:
Baseline
Reported as:
Count of participants · Participants
Number of Participants With Tumors Evaluable for PTEN
ParticipantsLapatinib 1500 mg + PaclitaxelPlacebo + Paclitaxel
PTEN IHC 02821
PTEN IHC 1+7680
PTEN IHC 2+/3+7674
SecondaryPredictive Effect of PIK3CA Mutations Status on Overall Response Rate (ORR)

ORR was evaluated per RECIST v1.1 and defined as the percentage of subjects achieving either CR or PR. Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. A PIK3CA mutation test kit was used to assess mutation status on genomic deoxyribonucleic acid (DNA) isolated from tumor tissue.

Time frame:
From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 53 months (Primary OS analysis cut-off date = 18-Jun-2010)
Reported as:
Number · percentage of participants
Predictive Effect of PIK3CA Mutations Status on Overall Response Rate (ORR)
percentage of participantsLapatinib 1500 mg + PaclitaxelPlacebo + Paclitaxel
PIK3CA mutation6250
PIK3CA wild-type8059
Statistical analysis
  • Lapatinib 1500 mg + Paclitaxel vs Placebo + Paclitaxel · Odds ratio (or): 2.78 · 95% CI 1.07 to 7.57
SecondaryPredictive Effect of PTEN Low on Overall Response Rate (ORR)

ORR was evaluated per RECIST v1.1 and defined as the percentage of subjects achieving either CR or PR. Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. Immunohistochemistry (IHC) staining in an analytically validated assay was used in the assessment of PTEN protein expression on tumor tissue. Staining intensity was allocated a score of 0, 1+, 2+ or 3+. Tumors scored IHC 0 were considered as exhibiting an absence of PTEN expression whereas those scored ICH 1+, 2+ or 3+ were considered as exhibiting any PTEN expression, being 3+ the highest expression. Tumors scored IHC 0/1+ were considered PTEN low.

Time frame:
From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 53 months (Primary OS analysis cut-off date = 18-Jun-2010)
Reported as:
Number · percentage of participants
Predictive Effect of PTEN Low on Overall Response Rate (ORR)
percentage of participantsLapatinib 1500 mg + PaclitaxelPlacebo + Paclitaxel
PTEN low7353
Without PTEN low7658
Statistical analysis
  • Lapatinib 1500 mg + Paclitaxel vs Placebo + Paclitaxel · Odds ratio (or): 2.42 · 95% CI 1.28 to 4.63
  • Lapatinib 1500 mg + Paclitaxel vs Placebo + Paclitaxel · Odds ratio (or): 2.21 · 95% CI 1.04 to 4.82
SecondaryPredictive Effect of PIK3CA Mutations Status on Clinical Benefit Rate (CBR)

CBR was evaluated per RECIST v1.1 and defined as the percentage of subjects achieving CR or PR or stable disease. Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. A PIK3CA mutation test kit was used to assess mutation status on genomic deoxyribonucleic acid (DNA) isolated from tumor tissue.

Time frame:
From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 53 months (Primary OS analysis cut-off date = 18-Jun-2010)
Reported as:
Number · percentage of participants
Predictive Effect of PIK3CA Mutations Status on Clinical Benefit Rate (CBR)
percentage of participantsLapatinib 1500 mg + PaclitaxelPlacebo + Paclitaxel
PIK3CA mutation6956
PIK3CA wild-type8465
SecondaryPredictive Effect of PTEN Low on Clinical Benefit Rate (CBR)

CBR was evaluated per RECIST v1.1 and defined as the percentage of subjects achieving CR or PR or stable disease. Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. Immunohistochemistry (IHC) staining in an analytically validated assay was used in the assessment of PTEN protein expression on tumor tissue. Staining intensity was allocated a score of 0, 1+, 2+ or 3+. Tumors scored IHC 0 were considered as exhibiting an absence of PTEN expression whereas those scored ICH 1+, 2+ or 3+ were considered as exhibiting any PTEN expression, being 3+ the highest expression. Tumors scored IHC 0/1+ were considered PTEN low.

Time frame:
From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 53 months (Primary OS analysis cut-off date = 18-Jun-2010)
Reported as:
Number · percentage of participants
Predictive Effect of PTEN Low on Clinical Benefit Rate (CBR)
percentage of participantsLapatinib 1500 mg + PaclitaxelPlacebo + Paclitaxel
PTEN low8259
Without PTEN low8061
Statistical analysis
  • Lapatinib 1500 mg + Paclitaxel vs Placebo + Paclitaxel · Odds ratio (or): 3.15 · 95% CI 1.58 to 6.49
  • Lapatinib 1500 mg + Paclitaxel vs Placebo + Paclitaxel · Odds ratio (or): 2.49 · 95% CI 1.13 to 5.66

Adverse events

Collected over From study treatment start date till 30 days safety follow-up, assessed up to 190 months (Final OS analysis cut-off date = 23-Nov-2021). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lapatinib 1500 mg + Paclitaxel10/222 (4.5%)67/222 (30.2%)219/222 (98.6%)
Placebo + Paclitaxel15/221 (6.8%)30/221 (13.6%)206/221 (93.2%)
Open Label - Monotherapy2/149 (1.3%)8/149 (5.4%)86/149 (57.7%)
Open Label - Combination Therapy0/4 (0%)0/4 (0%)3/4 (75%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventLapatinib 1500 mg + PaclitaxelPlacebo + PaclitaxelOpen Label - MonotherapyOpen Label - Combination Therapy
NeutropeniaBlood and lymphatic system disorders36/22210/2210/1490/4
Ejection fraction decreasedInvestigations13/2223/2210/1490/4
DiarrhoeaGastrointestinal disorders10/2220/2211/1490/4
LeukopeniaBlood and lymphatic system disorders7/2221/2210/1490/4
Febrile neutropeniaBlood and lymphatic system disorders6/2221/2210/1490/4
GranulocytopeniaBlood and lymphatic system disorders4/2220/2210/1490/4
Left ventricular dysfunctionCardiac disorders3/2220/2210/1490/4
PyrexiaGeneral disorders3/2220/2211/1490/4
Femur fractureInjury, poisoning and procedural complications0/2222/2210/1490/4
DyspnoeaRespiratory, thoracic and mediastinal disorders1/2222/2210/1490/4
Most frequent other events
Showing 10 of 47
Most frequent other events
EventLapatinib 1500 mg + PaclitaxelPlacebo + PaclitaxelOpen Label - MonotherapyOpen Label - Combination Therapy
DiarrhoeaGastrointestinal disorders172/22264/22142/1490/4
NeutropeniaBlood and lymphatic system disorders168/222103/2215/1490/4
AlopeciaSkin and subcutaneous tissue disorders104/222119/2212/1490/4
LeukopeniaBlood and lymphatic system disorders113/22274/2216/1490/4
Dry skinSkin and subcutaneous tissue disorders16/2223/2218/1492/4
RashSkin and subcutaneous tissue disorders109/22247/22152/1490/4
Decreased appetiteMetabolism and nutrition disorders70/22241/2213/1490/4
NauseaGastrointestinal disorders66/22244/2214/1490/4
Mucosal erosionGeneral disorders0/2220/2210/1491/4
Blood bilirubin increasedInvestigations7/2225/2212/1491/4

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Lapatinib 1500 mg + PaclitaxelPlacebo + PaclitaxelTotal
Mean49.1 ± 10.7449.3 ± 9.7549.2 ± 10.25
Sex: Female, Male
Sex: Female, Male(Participants)Lapatinib 1500 mg + PaclitaxelPlacebo + PaclitaxelTotal
Female222217439
Male055
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lapatinib 1500 mg + PaclitaxelPlacebo + PaclitaxelTotal
White91322
Asian192192384
Hispanic211637
Other011
Number of participants with any visceral metastatic disease and with only non-visceral disease
Number of participants with any visceral metastatic disease and with only non-visceral disease(Participants)Lapatinib 1500 mg + PaclitaxelPlacebo + PaclitaxelTotal
Visceral187186373
Non-visceral353671
Number of Participants with the Indicated Hormone Receptor Status
Number of Participants with the Indicated Hormone Receptor Status(Participants)Lapatinib 1500 mg + PaclitaxelPlacebo + PaclitaxelTotal
ER+ and/or PgR+ or Unknown111113224
ER- and PgR-111109220
Number of Participants with the Indicated Stage of Disease at Initial Diagnosis
Number of Participants with the Indicated Stage of Disease at Initial Diagnosis(Participants)Lapatinib 1500 mg + PaclitaxelPlacebo + PaclitaxelTotal
Stage I to II107119226
Stage III7568143
Stage IV302454
Unknown101121
Number of Participants with the Indicated Eastern Cooperative Oncology Group Performance Status
Number of Participants with the Indicated Eastern Cooperative Oncology Group Performance Status(Participants)Lapatinib 1500 mg + PaclitaxelPlacebo + PaclitaxelTotal
0, Fully Active103113216
1, Ambulatory, Restricted Strenuous Activity119109228
Number of Participants with the Indicated Number of Metastatic Sites
Number of Participants with the Indicated Number of Metastatic Sites(Participants)Lapatinib 1500 mg + PaclitaxelPlacebo + PaclitaxelTotal
Greater than or equal to 3131115246
Less than 391107198

1 further baseline measures are reported on the registry.

08

Study locations

54 sites
  • Novartis Investigative Site
    Salvador, Bahía 40.050-410, Brazil
  • Novartis Investigative Site
    Salvador, Bahía 40285-001, Brazil
  • Novartis Investigative Site
    Belo Horizonte, Minas Gerais 30150-281, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande Do Sul 90610 000, Brazil
  • Novartis Investigative Site
    Natal, Rio Grande Du Norte 59075-740, Brazil
  • Novartis Investigative Site
    Jau, São Paulo 17210-120, Brazil
  • Novartis Investigative Site
    Santo Andre, São Paulo 09060-650, Brazil
  • Novartis Investigative Site
    Sao Paulo, São Paulo 01221-020, Brazil
  • Novartis Investigative Site
    Sao Paulo, São Paulo 03102-002, Brazil
  • Novartis Investigative Site
    Guangzhou, Guangdong 510060, China
  • Novartis Investigative Site
    Wuhan, Hubei 430030, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210002, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210009, China
  • Novartis Investigative Site
    Dalian, Liaoning 116027, China
  • Novartis Investigative Site
    Xi'an, Shaanxi 710032, China
  • Novartis Investigative Site
    Xi'an, Shaanxi 710061, China
  • Novartis Investigative Site
    Jinan, Shandong 250012, China
  • Novartis Investigative Site
    Jinan, Shandong 250031, China
  • Novartis Investigative Site
    Jinan, Shandong 250117, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310022, China
  • Novartis Investigative Site
    Beijing, 100021, China
  • Novartis Investigative Site
    Beijing, 100036, China
  • Novartis Investigative Site
    Beijing, 100071, China
  • Novartis Investigative Site
    Beijing, 100853, China
  • Novartis Investigative Site
    Chengdu, 610041, China
  • Novartis Investigative Site
    Chongqing, 400037, China
  • Novartis Investigative Site
    Dalian, 116011, China
  • Novartis Investigative Site
    Fuzhou, 350001, China
  • Novartis Investigative Site
    Fuzhou, 350014, China
  • Novartis Investigative Site
    Shanghai, 200032, China
  • Novartis Investigative Site
    Shanghai, 200070, China
  • Novartis Investigative Site
    Shanghai, 200433, China
  • Novartis Investigative Site
    Shenyang, 110015, China
  • Novartis Investigative Site
    Tianjin, 300060, China
  • Novartis Investigative Site
    Kowloon, Hong Kong
  • Novartis Investigative Site
    Pokfulam, Hong Kong
  • Novartis Investigative Site
    Tuen Mun, Hong Kong
  • Novartis Investigative Site
    Lahore, 53400, Pakistan
  • Novartis Investigative Site
    Lahore, 54600, Pakistan
  • Novartis Investigative Site
    Lahore, Pakistan
  • Novartis Investigative Site
    Lima, Lima 34, Peru
  • Novartis Investigative Site
    Kazan, 420029, Russian Federation
  • Novartis Investigative Site
    Moscow, 117997, Russian Federation
  • Novartis Investigative Site
    Moscow, 125101, Russian Federation
  • Novartis Investigative Site
    Moscow, 143423, Russian Federation
  • Novartis Investigative Site
    Rostov-na-Donu, 344037, Russian Federation
  • Novartis Investigative Site
    Samara, 443031, Russian Federation
  • Novartis Investigative Site
    Voronezh, 394062, Russian Federation
  • Novartis Investigative Site
    Bangkok, 10400, Thailand
  • Novartis Investigative Site
    Chiangmai, 50200, Thailand
  • Novartis Investigative Site
    Cherkasy, 18009, Ukraine
  • Novartis Investigative Site
    Chernihiv, 14029, Ukraine
  • Novartis Investigative Site
    Dnipropetrovsk, 49055, Ukraine
  • Novartis Investigative Site
    Zaporizhzhia, 69040, Ukraine
09

References and documents

Publications

  • Xu B, Guan Z, Shen Z, Tong Z, Jiang Z, Yang J, DeSilvio M, Russo M, Leigh M, Ellis C. Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone. Breast Cancer Res. 2014 Jul 24;16(4):405. doi: 10.1186/s13058-014-0405-y. PubMed 25056500 ↗
  • Guan Z, Xu B, DeSilvio ML, Shen Z, Arpornwirat W, Tong Z, Lorvidhaya V, Jiang Z, Yang J, Makhson A, Leung WL, Russo MW, Newstat B, Wang L, Chen G, Oliva C, Gomez H. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol. 2013 Jun 1;31(16):1947-53. doi: 10.1200/JCO.2011.40.5241. Epub 2013 Mar 18. PubMed 23509322 ↗

Related links

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2006 to primary completion in Jun 2010, 53 months.

Results were first posted in Jun 2011, 11 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 53 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2006
First posted
Jan 25, 2006
StartActual
Jan 2, 2006
Primary completionActual
Jun 18, 2010
CompletionActual
Nov 23, 2021
Results first posted
Jun 1, 2011
Last update
Feb 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00281658
Responsible party
Sponsor
First posted
Jan 25, 2006
Start date
Jan 2, 2006
Primary completion
Jun 18, 2010
Completion
Nov 23, 2021
Results posted
Jun 1, 2011
Last update
Feb 10, 2023

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lapatinib · Paclitaxel

Start the discussion